Digestome therapeutics address
WebFeb 25, 2024 · SAN FRANCISCO, Feb. 25, 2024 /PRNewswire/ -- Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central … WebAbout. Digestome Therapeutics is Drug Discovery in Japan that focus on operator business. Founded in 2024. They cover business area such as operator, drug, psychiatric and inflammatory disease, development, depression, anxiety, gastrointestinal disease, researcher, doctor, access, area, unmet medical need.
Digestome therapeutics address
Did you know?
WebMr. Taka Koda serves as Chief Financial Officer & President of Japan at Digestome Therapeutics. Mr. Koda serves as Partner at Remiges Ventures. He is a Board Member at Immunis. He has 15+ years healthcare investment experience, multiple CEO experiences. He also previously worked at Mitsui's private equity group both in US and Japan. WebDigestome Therapeutics is a private biotech company developing first-in-class therapeutics targeting a clinically proven mechanism, VNS (vagus nerve stimulation). VNS has been FDA approved in ...
WebMar 8, 2024 · milestone for Digestome and our first-in-class gut-brain-axis therapeutic platform,” said Ken Horne, President of Digestome Therapeutics. “This is an important first step towards helping negative symptoms and cognitive impairment in schizophrenia patients, as well as non-motor symptoms in Parkinson’s Disease patients. WebMar 7, 2024 · View Igor Grachev's business profile as Chief Medical Officer at Digestome Therapeutics. Find contact's direct phone number, email address, work history, and …
WebDigestome Therapeutics is a private biotech company developing first-in-class therapeutics targeting a clinically proven mechanism, VNS (vagus nerve stimulation). VNS has been FDA approved in epilepsy and depression, and is in trials for other psychiatric, neurodegenerative and inflammatory diseases. However, the products are medical … WebMar 8, 2024 · This represents significant clinical milestone for Digestome and our first-in-class gut-brain-axis therapeutic platform," said Ken Horne, President of Digestome Therapeutics. "This is an important ...
WebPrior to Vincerx, he was active in company creation as President of Digestome Therapeutics and as an advisor to multiple early stage biotechs pioneering first-in-class therapies to address unmet patient needs including T-Cure, Quadriga, and Pellepharm.
WebDIGESTOME THERAPEUTICS, INC. is a Massachusetts Foreign Corporation filed on January 3, 2024. The company's File Number is listed as 001306399. The Registered Agent on file for this company is Corp2000 and is located at 1900 West Park Dr., Ste. 280b, Westborough, MA 01581. The company's principal address is One Broadway, 14th Flr., … money sponsorWebContact Info. 387 Technology Circle NW Suite 125 Atlanta, Georgia 30313. [email protected]. PRODUCT INQUIRIES. To report an adverse event, … money sponsorshipWebMarch 8, 2024. Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system (CNS) via the gut-brain-axis, announced that the first patient has been enrolled … moneyspot australiaWebMar 3, 2024 · Dr. James Henry Degerome III 2708 S Seacrest Blvd Boynton Beach, FL 33435. (561) 732-4452. Dr. James Henry Degerome III 1325 S Congress Ave Boynton … icpop hubsWebJan 6, 2024 · Digestome Therapeutics Completes $10 Million Seed Financing SAN FRANCISCO, CA, January 6, 2024 – Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate mind via the gut-brain-axis, announced today the completion of a $10M Seed financing to advance its lead program into clinical … icp measuring deviceWebMar 8, 2024 · milestone for Digestome and our first-in-class gut-brain-axis therapeutic platform,” said Ken Horne, President of Digestome Therapeutics. “This is an important … moneyspot finance linkedinWebFeb 25, 2024 · "Digestome is excited to work with Zhongze Therapeutics to develop DGX-001 for the greater China markets," said Ken Horne, President of Digestome … moneyspire review 2020